Quantitative Cardiac Magnetic Resonance Imaging in Finding Heart Complications in Patients with Breast Cancer Receiving Chemotherapy
This research trial studies quantitative cardiac magnetic resonance imaging in finding heart complications in patients with breast cancer receiving chemotherapy. One of the side effects in patients receiving chemotherapy is heart complications in which the heart muscle is weakened and no longer able to pump sufficient amounts of blood throughout the body, which can lead to shortness of breath, swollen ankles and feet, lack of energy, and a reduced capacity to carry out day-to-day activities. Identifying early signs of such heart complications using cardiac magnetic resonance may allow preventative treatment options to be made available in future.
- Histologic diagnosis of breast carcinoma
- Scheduled to receive standard clinical therapy designed by their treating oncologist
- Patients should receive anthracycline as part of the recommended treatment
- Able to give informed consent
- Contraindication to contrast CMR including estimated glomerular filtration rate (eGFR) < 30 mls/min/1.73 m^2
- Uncontrolled serious concurrent illness
- Pregnancy or breast feeding
Locations & Contacts
Contact: Reza Nezafat
Trial Objectives and Outline
I. To quantify the distributions and temporal changes of cardiac magnetic resonance (CMR) parameters during chemotherapy.
II. To identify CMR predictors of cardiotoxicity in patients receiving anthracycline +/- neoadjuvant therapy.
III. Demonstrate the incremental predictive value of CMR versus (vs.) transthoracic echocardiogram (TTE) and serum biomarkers in cardiotoxicity.
Patients undergo CMR at baseline, after completion anthracycline treatment, immediately after completion of all treatments (patients may receive targeted HER2+ positive treatment or other treatments between 3rd and 4th scans), and 12 months after completion of treatment.
After completion of study treatment, patients are followed up in 1 and 2 year intervals.
Trial Phase & Type
No phase specified
Dana-Farber Harvard Cancer Center
Secondary IDs NCI-2016-00297
Clinicaltrials.gov ID NCT02666378